Who is sponsoring EBSCPVCIND?

EBSCPVCIND is sponsored by The Second Hospital of Hebei Medical University.

What condition does EBSCPVCIND study?

EBSCPVCIND studies Vascular Cognitive Impairment no Dementia.

What drugs are being tested in EBSCPVCIND?

Interventions: Butylphthalide Soft Capsules, Placebo Butylphthalide Soft Capsules.

What is the status of EBSCPVCIND?

EBSCPVCIND is currently UNKNOWN.

Last reviewed 2017-03-15 · How we verify

The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND:A Randomized, Double-blind,and Neuroimaging Study (EBSCPVCIND)

NCT02993367 Phase 2/Phase 3 UNKNOWN

Vascular cognitive impairment no dementia (VCIND) is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. VCIND caused by subcortical ischemic small vessel disease (hereinafter, subcortical VCIND) represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating VCIND. Preclinical trials showed that Butylphthalide Soft Capsules is effective for cognitive impairment of vascular origin. In this randomized, double-blind, placebo-controlled trial, the investigators apply fMRI study the effects of Butylphthalide Soft Capsules in patients with VCIND.

Details

Lead sponsor	The Second Hospital of Hebei Medical University
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	200
Start date	2017-01
Completion	2019-07

Conditions

Vascular Cognitive Impairment no Dementia

Interventions

Butylphthalide Soft Capsules
Placebo Butylphthalide Soft Capsules

Primary outcomes

change of Cognitive function — Time points 0, 1, 3 and 6 months

Countries

China